Julian Harrison
Stock Analyst at BTIG
(4.96)
# 108
Out of 4,408 analysts
499
Total ratings
54.1%
Success rate
44.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintained: Buy | $98 → $112 | $83.41 | +34.28% | 21 | Jun 15, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintained: Buy | $150 | $97.50 | +53.85% | 14 | Jun 15, 2026 | |
| CLYM Climb Bio | Maintained: Buy | $19 → $20 | $10.71 | +86.74% | 8 | Jun 11, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $38 | $13.55 | +180.44% | 24 | Jun 10, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $44 | $9.05 | +386.19% | 9 | Jun 9, 2026 | |
| LQDA Liquidia | Maintained: Buy | $59 | $68.01 | -13.25% | 44 | Jun 4, 2026 | |
| RZLT Rezolute | Maintained: Buy | $5 → $6 | $4.57 | +31.29% | 16 | Jun 2, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $39 → $74 | $15.53 | +376.50% | 18 | Jun 1, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $137 | $85.24 | +60.72% | 26 | May 27, 2026 | |
| INVA Innoviva | Rated: Buy | $42 | $22.61 | +85.76% | 3 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.57 | - | 19 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $151 | $67.71 | +123.01% | 11 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $14.33 | +304.75% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.99 | +402.51% | 5 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $18.98 | +58.06% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $2.63 | +470.34% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $178 | $60.27 | +195.34% | 17 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $16.70 | +25.75% | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $0.984 | +306.50% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $23.89 | +92.55% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.292 | +242.47% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $548.27 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $5.67 | +199.82% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $15.98 | +281.73% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $82 | $110.64 | -25.89% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6402 | - | 7 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $0.7597 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $163 | $45.01 | n/a | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $10.03 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $57.61 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $4.34 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $6.28 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.7202 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.0001 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $29.65 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $1.78 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.19 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $4.18 | n/a | 1 | Dec 9, 2020 |
Spyre Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $98 → $112
Current: $83.41
Upside: +34.28%
ABIVAX Société Anonyme
Jun 15, 2026
Maintained: Buy
Price Target: $150
Current: $97.50
Upside: +53.85%
Climb Bio
Jun 11, 2026
Maintained: Buy
Price Target: $19 → $20
Current: $10.71
Upside: +86.74%
Cullinan Therapeutics
Jun 10, 2026
Reiterated: Buy
Price Target: $38
Current: $13.55
Upside: +180.44%
Cartesian Therapeutics
Jun 9, 2026
Reiterated: Buy
Price Target: $44
Current: $9.05
Upside: +386.19%
Liquidia
Jun 4, 2026
Maintained: Buy
Price Target: $59
Current: $68.01
Upside: -13.25%
Rezolute
Jun 2, 2026
Maintained: Buy
Price Target: $5 → $6
Current: $4.57
Upside: +31.29%
Jade Biosciences
Jun 1, 2026
Maintained: Buy
Price Target: $39 → $74
Current: $15.53
Upside: +376.50%
Apogee Therapeutics
May 27, 2026
Maintained: Buy
Price Target: $137
Current: $85.24
Upside: +60.72%
Innoviva
May 26, 2026
Rated: Buy
Price Target: $42
Current: $22.61
Upside: +85.76%
May 18, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.57
Upside: -
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $67.71
Upside: +123.01%
May 13, 2026
Maintained: Buy
Price Target: $58
Current: $14.33
Upside: +304.75%
May 12, 2026
Maintained: Buy
Price Target: $10
Current: $1.99
Upside: +402.51%
May 11, 2026
Reiterated: Buy
Price Target: $30
Current: $18.98
Upside: +58.06%
May 8, 2026
Maintained: Buy
Price Target: $15
Current: $2.63
Upside: +470.34%
May 7, 2026
Maintained: Buy
Price Target: $178
Current: $60.27
Upside: +195.34%
May 7, 2026
Maintained: Buy
Price Target: $21
Current: $16.70
Upside: +25.75%
Apr 6, 2026
Maintained: Buy
Price Target: $4
Current: $0.984
Upside: +306.50%
Mar 25, 2026
Maintained: Buy
Price Target: $46
Current: $23.89
Upside: +92.55%
Mar 19, 2026
Maintained: Buy
Price Target: $1
Current: $0.292
Upside: +242.47%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $548.27
Upside: -
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $5.67
Upside: +199.82%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $15.98
Upside: +281.73%
Nov 3, 2025
Maintained: Buy
Price Target: $82
Current: $110.64
Upside: -25.89%
Jul 31, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.6402
Upside: -
Mar 31, 2025
Maintained: Buy
Price Target: $14
Current: $0.7597
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $163
Current: $45.01
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $10.03
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $57.61
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $4.34
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $24
Current: $6.28
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.7202
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.0001
Upside: n/a
Apr 28, 2021
Maintained: Buy
Price Target: $12
Current: $29.65
Upside: n/a
Apr 27, 2021
Maintained: Buy
Price Target: $29
Current: $1.78
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.19
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $4.18
Upside: n/a